Pressure Ulcers Treatment Market Size

Pressure Ulcers Treatment Market Analysis

The Pressure Ulcers Treatment Market size is estimated at USD 5.65 billion in 2024, and is expected to reach USD 7.47 billion by 2029, growing at a CAGR of 5.75% during the forecast period (2024-2029).

At the beginning of 2020, the outbreak of COVID-19 worldwide impacted the market studied, as wound care services, such as pressure ulcer treatments, were put on hold to prevent the spread of the COVID-19 virus. This situation put tremendous pressure on hospitals and other healthcare centers to provide services to COVID-19 patients. According to the January 2021 research article titled 'Pressure Injury Prevention in COVID-19 Patients With Acute Respiratory Distress Syndrome,' it was found that most of the COVID-19 infected people may have mild symptoms, while older people and people with chronic illnesses may develop acute respiratory distress syndrome (ARDS). Patients with ARDS with worsening hypoxemia require prone positioning to improve the respiratory mechanics and oxygenation. Intubated patients may stay in a prone position for up to 12-16 hours, increasing the risk of pressure injury (PI). Thus, the increasing incidence of pressure ulcers among COVID-19 patients is driving the demand for pressure ulcers treatments. Moreover, in November 2020, a collaborative effort between örebro University, örebro University Hospital and Ghent University issued new global guidelines for preventing pressure ulcers and other complications in patients receiving respiratory support. Though, the market experienced a significant decline during the initial days of the pandemic, later on, the increased incidence of pressure ulcers among COVID-19 patients created a huge demand for pressure ulcers treatment.

Pressure ulcers also are known as bedsores or pressure sores, are injuries caused to skin and tissues primarily caused by prolonged pressure on the skin. Pressure ulcers can range in severity from patches of discolored skin to open wounds that expose the underlying bone or muscle. The geriatric population is more prone to the development of pressure ulcers that are also known as bedsores. The number of people aged 60 years and above has been substantially increasing in recent years in most of the regions, and it is expected to keep growing over the coming years. For instance, according to the Centers for Disease Control and Prevention (CDC) in August 2020, around one in 10 seniors with limited mobility developed bedsores. This factor will be contributing to the market growth. Additionally, as per the data published by the United States Department of Health and Human Services in 2020, around 2.5 million people in the United States were affected by pressure ulcers every year. Moreover, the treatments for these ulcers cost more than around USD 9.1-11.6 billion every year in the United States. These alarming expenses are contributing to the rising demand for bedsore management treatment.

Also, the increasing concentration of major players in the market and the active investments of these companies in the research and development activities for the innovation of novel wound care products act as major driving factors for the market. For instance, in January 2020, the company ConvaTec Group PLC announced the launch of ConvaMax, which is the new superabsorber wound dressing extensively used in the management of highly exuding wounds, including leg ulcers, pressure ulcers, diabetic foot ulcers, and dehisced surgical wounds. Additionally, in November 2021, the company Sanara MedTech Inc. announced the commercial launch of two new innovative extracellular matrix products (FORTIFY TRGTM Tissue Repair Graft & FORTIFY FLOWABLETM Extracellular Matrix) in partnership with Cook Biotech Inc. Thus, the introduction of such technologically advanced devices will increase the demand for wound care products.

Therefore, the technological advancements in wound care therapy and an increase in the geriatric population are the key driving factors in the pressure ulcer treatment market.